Education
About Us
Working with TipRanks
Follow Us
bluebird bio (BLUE)
NASDAQ:BLUE
BLUE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.56 - $33.18
Previous CloseN/A
Volume68.97K
Average Volume (3M)444.69K
Market Cap
$37.21M
Enterprise Value$390.74M
Total Cash (Recent Filing)$402.58M
Total Debt (Recent Filing)$154.74M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 07, 2025EPS Estimate
-6.15Last Dividend Ex-Date
Nov 05, 2021Dividend YieldN/A
Share Statistics
EPS (TTM)-35.97
Shares Outstanding9,740,894
10 Day Avg. Volume925,495
30 Day Avg. Volume444,687
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.70
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap10.50
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-96.96
Enterprise Value/Ebitda-3.05
Forecast
1Y Price Target
$13.60Price Target Upside230.90% Upside
Rating ConsensusHold
Number of Analyst Covering7
---
Bulls Say, Bears Say
Bulls Say
Cost ReductionCost reduction efforts should reduce operating expenses by 20% and allow for break-even to be achieved.
PrivatizationThe announced privatization of the company is expected to be completed within the first half of 2025.
Product ReachBLUE has activated more than 70 QTCs for Zynteglo and Lyfgenia, indicating a broader treatment reach.
Bears Say
Financial Performance3Q24 revenue of $10.6mm was below the expected $21.1mm and continues to decline sequentially QoQ from $16.1mm in 2Q24 and $18.6mm in 1Q24.
LiquidityBLUE needs additional cash resources to extend its cash runway for breakeven.
Sales EstimatesSales estimates for Lyfgenia are reduced due to slower-than-expected uptake in sickle-cell disease.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
BLUE FAQ
What was bluebird bio’s price range in the past 12 months?
bluebird bio lowest stock price was $3.56 and its highest was $33.18 in the past 12 months.
What is bluebird bio’s market cap?
bluebird bio’s market cap is $37.21M.
When is bluebird bio’s upcoming earnings report date?
bluebird bio’s upcoming earnings report date is May 07, 2025 which is in 61 days.
How were bluebird bio’s earnings last quarter?
Currently, no data Available
Is bluebird bio overvalued?
According to Wall Street analysts bluebird bio’s price is currently Undervalued.
Does bluebird bio pay dividends?
bluebird bio pays a Notavailable dividend of $177.66 which represents an annual dividend yield of N/A. See more information on bluebird bio dividends here
What is bluebird bio’s EPS estimate?
bluebird bio’s EPS estimate is -6.15.
How many shares outstanding does bluebird bio have?
bluebird bio has 9,740,894 shares outstanding.
What happened to bluebird bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of bluebird bio?
Among the largest hedge funds holding bluebird bio’s share is Graham Capital Management, L.P.. It holds bluebird bio’s shares valued at 0.
---
Bluebird Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.60 (230.90% Upside)
$13.60 (230.90% Upside)
Blogger Sentiment
Bullish
BLUE Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 66.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $14.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.61%
12-Months-Change
Fundamentals
Return on Equity
-270.20%
Trailing 12-Months
Asset Growth
-24.21%
Trailing 12-Months
Company Description
bluebird bio
bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
---
BLUE Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong patient start growth, successful cost reduction efforts, and promising reimbursement pathways. However, these positives were countered by a decrease in quarterly revenue, cash resource challenges, and pending shareholder approvals, creating a balanced outlook.Read More>---
BLUE Stock 12 Month Forecast
Average Price Target
$13.60
▲(230.90% Upside)
Technical Analysis
Sangamo Biosciences
―
Vertex Pharmaceuticals
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering BLUE
1 Year
1 Year Success Rate
10/25 ratings generated profit
1 Year Average Return
+22.63%
reiterated a buy rating 2 months ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +22.63% per trade.
---